1 2	J. Tom Boer (State Bar No. 199563)	
3	tom.boer@hoganlovells.com Maia H. Jorgensen (State Bar No. 344980)	
4	maia.jorgensen@hoganlovells.com 4 Embarcadero Center, Suite 3500	
5	San Francisco, California 94111 Telephone: (415) 374-2300	
6	Facsimile: (415) 374-2499	
7	Attorneys for Petitioner	
8	B. BRAUN US PHARMACEUTICAL MANUFA	CTURING LLC
9	BEFORE THE HEARING BOARD OF THE	
10	SOUTH COAST AIR QUALITY MANAGEMENT DISTRICT	
11	In the Matter of	Case No. 4780-5
12	B. BRAUN US PHARMACEUTICAL	[PROPOSED] FINDINGS AND
13	MANUFACTURING LLC [Facility ID No. 117290]	DECISION
14	Petitioner,	South Coast AQMD Rule 1134
15	VS.	Hearing Date: October 24, 2024 Time: 9:30 a.m.
16	SOUTH COAST AIR QUALITY	Place: Hearing Board
17	MANAGEMENT DISTRICT,	South Coast Air Quality Management District
18	Respondent.	21865 Copley Drive Diamond Bar, CA 91765
19		2
20	FINDINGS AND DECISION OF THE HEARING BOARD	
21	On December 19, 2023, a Petition for a Regular Variance ("Petition") was heard, pursuant to	
22	notice and in accordance with the provisions of the California Health and Safety Code section 40826	
23	and South Coast AQMD Rule 510. The Petition was subsequently granted, and a regular variance	
24	was issued by the Hearing Board on December 21	, 2023. On May 29, 2024, B. Braun Medical Inc.
25	("BMI") notified the Hearing Board that ownership and operation of its pharmaceutical	
26	manufacturing facility located at 2525 McGaw Avenue in Irvine, California (the "Irvine Facility"),	
27	which is subject to the variance, was transferred to an affiliate entity, B. Braun US Pharmaceutical	
28	Manufacturing LLC ("Petitioner" or "Pharma"). Pharma is now responsible for compliance with the	

1	variance. On August 30, 2024, Pharma filed a Petition for Extension of a Final Compliance Deadline,
2	in connection with the variance (the "Extension Petition"). On October 24, 2024, the Hearing Board
3	held a hearing pursuant to California Health and Safety Code section 40826 and South Coast AQMD
4	Rule 510, to consider an extension of the variance compliance deadlines, as requested in the
5	Extension Petition. The following members of the Hearing Board were present: Micah Ali, Chair;
6	Robert Pearman, Vice-Chair; Mohan Balagopalan; Jerry P. Abraham, MD; and Cynthia Verdugo-
7	Peralta. Petitioner, represented by J. Tom Boer, Esq., and Maia Jorgensen, Esq., Hogan Lovells US
8	LLP, did not appear. Respondent, Executive Officer of the South Coast Air Quality Management
9	District ("South Coast AQMD" or "Respondent"), represented by Mary Reichert, Senior Deputy
10	District Counsel, did not appear. The parties have stipulated to the issuance of this Order. The public
11	was given the opportunity to testify. Evidence was received and the matter was submitted. The
12	Hearing Board finds and decides as follows:

Nature of Business and Location of Facility

Petitioner Pharma is a medical equipment manufacturing company operating the Irvine Facility, which is a modernized, 710,000 sq. ft. pharmaceutical manufacturing facility located in Irvine, California, within the jurisdiction of the South Coast AQMD. The Facility ID Number is 117290.

Equipment and Permit to Construct/Operate

The equipment that is the subject of the variance consists of Turbine No. 1 (Device D28) operated pursuant to Permit to Operate No. 432956 and Turbine No. 2 (Device D35) operated pursuant to Permit to Operate No. 542242 (collectively, the "Turbines").

South Coast AQMD Rule 1134 requires an emission standard of 2 ppm NOx @ 15% O2 for all stationary Natural Gas-Fueled Cogeneration Single Cycle Turbines effective January 1, 2024.

SUMMARY

Petitioner is in violation of District Rule 1134 because Turbines No. 1 and 2 do not meet the Rule 1134 2 ppm NOx limitation that took effect on January 1, 2024. Petitioner must continue to operate Turbines No. 1 and 2 because delivery and installation of the replacement technology was not completed in time to meet the January 1, 2024 deadline. Despite an initial estimate of completion

that would have met the January 1, 2024 deadline, Petitioner's contractor notified them that they would be unable to complete delivery and installation of compliant equipment until October 2024. This resulted in a final compliance deadline for the variance of October 31, 2024. Since issuance of the regular variance on December 21, 2023, BMI and Petitioner have diligently pursued installation of replacement technology that will bring the facility into compliance with District rules and allow for the decommissioning of the Turbines. Nevertheless, for reasons outside of Petitioner's control, Pharma has been made aware that certain required upgrades to the Southern California Edison ("SCE") electrical yard at the Irvine Facility will delay operationalization of replacement technology until January 2025.

FINDINGS OF FACT AND CONCLUSIONS

Following are the facts and conclusions supporting the findings set forth in Health and Safety Code Section 42352 necessary to grant the variance. The Executive Officer did not oppose the granting of the regular variance.

a. The Petitioner for a variance is or will be in violation of Section 41701, or of any rule, regulation, or order of the South Coast AQMD.

Petitioner is in violation of District Rule 1134 because Turbines No. 1 and 2 do not meet the Rule 1134 2 ppm NOx limitation that took effect on January 1, 2024. Petitioner must continue to operate Turbines No. 1 and 2 because delivery and installation of the replacement technology was not completed in time to meet the January 1, 2024 deadline.

b(1). Non-compliance with District Rule(s) is due to conditions beyond the reasonable control of the Petitioner.

BMI began a process in late 2018 to identify a feasible alternative for power generation at the Irvine Facility as required to meet the Rule 1134 deadline. BMI signed an Energy Services Agreement ("ESA") with Bloom Energy ("Bloom") to replace Turbines No. 1 and 2 with two natural gas fuel cell systems (the "Fuel Cells") to comply with the Rule 1134 2 ppm limit. When signing the contract in December 2022, Bloom agreed to a penalties provision in the ESA in the event the Fuel Cells are not operational within 18 months. However, in the second quarter of 2023, it became evident to BMI that Bloom would not meet the January 1, 2024 deadline. The project delay was

1 d p m 4 p

23 | 24 |

driven by a number of converging factors including unexpected complications with the City of Irvine permitting process (due to the City changing its position by requiring a City Master Plan modification process before issuing otherwise required permits for the project), longer than expected procurement lead times for electrical switchgears necessary for the project, and unanticipated challenges with various aspects of the project design including gas supply engineering.

Since issuance of the regular variance on December 21, 2023, BMI and Petitioner have diligently pursued installation of replacement technology that will bring the Irvine Facility into compliance with District rules and allow for the decommissioning of the Turbines. Certain aspects of the project, however, rely upon work performed by SCE. Such work is performed based upon the availability of SCE personnel and resources and is outside the direct control of Petitioner. Despite Petitioner's best efforts, in May of 2024, SCE notified Petitioner that certain structural and electrical upgrades must be completed at the SCE yard located adjacent to the Irvine Facility's Switchyard A before SCE will allow tie-in of the Fuel Cells into the electrical grid, which is an essential step to operationalizing the Fuel Cells. Based on estimates provided by SCE, it is contemplated that the necessary upgrades will be completed by the end of December 2024, after which the Fuel Cells can be energized. Bloom estimates a month will be required after energization of the Fuel Cells to complete the project. These unexpected project delays, which were outside Petitioner's control, form the basis of Petitioner's request for an extension of the final variance compliance deadline to January 31, 2025.

b(2). Requiring compliance would result in either (1) an arbitrary or unreasonable taking of property, or (2) the practical closing and elimination of a lawful business.

Petitioner's Irvine Facility produces over 100 medical products including premixed intravenous (IV) solutions, generic drugs, antibiotics, and nutrition therapy formulations. The Facility plays a critical role in the health care sector, as it produces approximately 20 percent of the IV solutions used in the United States. The Facility operates twenty-four hours a day, seven days a week, relying heavily on consistent energy generated by its two natural gas-fueled Turbines. These turbines are essential for the operation of the Facility. Shutting down of the Turbines without alternative power could result in \$2 million per day of lost revenues and significant disruption to the

c. The closing or taking would be without a corresponding benefit in reducing air contaminants.

 Estimated excess emissions are 9.77 pounds of NOx per day. This is not a significant amount of emissions when weighed against the significant impacts of a potential shutdown of the Facility.

There are also long-term benefits to the Facility's decision to replace its natural gas-fueled Turbines with the Fuel Cells as compared to installing replacement cogeneration turbines. Once installed, NOx emissions for the Fuel Cells will be approximately 0.0017 lbs/MWh, which will result in annual emissions that are significantly below the Rule 1134 limit. Within a year of the installation and start-up of the Fuel Cells, emissions saving from the conversion to the Fuel Cells will effectively cancel out the excess NOx emissions expected to be generated by the Turbines during the original 10-month variance period. After that one-year period, NOx emissions associated with the Fuel Cells will continue to be orders of magnitude less than the annual NOx emissions that would have occurred if Pharma had instead installed cogeneration turbines compliant with the newly effective January 1, 2024, NOx emission limitations for cogeneration turbines. The limited, additional excess NOx emissions generated during a three-month extension of the variance through January 31, 2025, will not materially change the benefits of the Fuel Cell project as recognized in the original variance.

d. The Petitioner for the variance has given consideration to curtailing operations of the source in lieu of obtaining a variance.

Curtailing or terminating operations at the Irvine Facility would have serious medical supply chain implications, result in breach of customer contracts, and have severe financial repercussions for Pharma. Several of the products Petitioner manufacturers at the Irvine Facility are or have recently been on the FDA drug shortages list. Curtailing operations would have a negative impact on millions of patients across California and the United States.

e. During the period the variance is in effect, the Petitioner will reduce excess emissions to the maximum extent feasible.

The Turbines have a permitted, maximum rated capacity of 6MW. During the variance

Petitioner shall maintain records of NOx emissions in pounds per day, and fuel usage records in million cubic feet per day, for each Turbine Device ID D28 and D35 starting Paolo Longoni(plongoni@aqmd.gov) on a quarterly basis, no later than close of business (COB) on the 5th day of the month following the end of each quarter.

23

24

25

26

27

2. Petitioner shall calculate NOx excessive emissions, in pounds per day, for each Turbine Device ID D28 and D35 starting 01/01/24 using the difference between the current NOx limit of 9 ppm (as set by Permit to Operate condition no. A99.1) and the future NOX limit of 2 ppm (as set by Rule 1134). These records shall be emailed to Air Quality Inspector Paolo Longoni

28

January 29, 2025: Fuel Cells microgrid transfer complete.

1	Within two business days of the deadline for the completion of each Increment of Progress,	
2	Petitioner shall submit via email to Air Quality Inspector Paolo Longoni (plongoni@aqmd.gov) an	
3	updated Gantt chart for the Fuel Cells project.	
4	9. Petitioner shall install and begin initial operation of the two new Fuel Cells	
5	no later than COB January 4, 2025.	
6	10. Petitioner shall achieve final compliance no later than COB January 31, 2025.	
7	Petitioner shall notify by email Air Quality Inspector Paolo Longoni (plongoni@aqmd.gov) of the	
8	following events as they occur:	
9	a. The construction start date, the installation completion date, and the date	
10	each new Fuel Cell becomes operational; and	
11	b. Achieving final compliance.	
12	11. Petitioner shall notify the Clerk of the Hearing Board at	
13	clerkofboard@aqmd.gov when final compliance is achieved.	
14	12. Petitioner shall pay any excess emissions fees to the Clerk of the Board on a	
15	quarterly basis no later than COB on the 30th day of the month following the end of each quarter or	
16	this variance shall be invalidated pursuant to Rule 303(k). The first payment will be due be due on	
17	April 30, 2024.	
18		
19	FOR THE BOARD:	
20	DATE SIGNED:	
21		
22		
23		
24		
25		
26		
27		
28		